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Renal cell carcinoma (RCC) comprises a range of histologically, molecularly, and clinically distinct malignancies arising from the nephron, the basic functional unit of the 
kidney. Clear cell (cc) and papillary (types I and II) RCCs originate in the proximal tubule and account for 90% of all cases. Translocation RCCs involving TFE3 or TFEB gene 
fusions can present clear cell or papillary histology usually, but not exclusively in young adults. Chromophobe RCCs (5%) and renal oncocytomas (<1%) arise in the distal 
tubule and are associated with an indolent disease course and excellent prognosis. Collecting duct and medullary RCCs (<1%) originate in the medulla and are character-
ized by an aggressive disease course and poor survival. Approximately 5% of all RCC cases are hereditary and are associated with well-described germline mutations and 
autosomal-dominant disorders, including VHL in von Hippel-Lindau disease and MET and FH in hereditary papillary RCC. The incidence of RCC is on the rise, mainly due to 
the rising incidence of the associated risk factors such as hypertension, smoking, and obesity. Despite increased detection of early disease, ~25% of patients present with 
metastatic disease. One-third of patients who undergo nephrectomy with curative intent will relapse. Median survival of patients with advanced disease is 18–24 months.
Mutational Landscape and Key Genes and Pathways
Clear Cell
There are overlaps in the genes implicated in familial and sporadic forms of ccRCC. Most significantly, VHL is mutated or methylated in ~80% of all sporadic cases, with 
loss of heterozygosity occurring through loss of 3p, the most commonly detected copy-number variant (CNV) (~90% of cases). TCEB1, which encodes Elongin C, part of 
the VHL-containing complex that targets hypoxia-inducible factor (HIF) for degradation, is mutated in 1%–5% of cases. TCEB1 mutations are mutually exclusive with VHL 
mutations and 3p loss and are instead accompanied by loss of 8q21.11, where TCEB1 is located. These observations highlight the central role of the HIF pathway in ccRCC 
tumorigenesis. The second most frequently mutated gene is PBRM1, which encodes BAF180, a subunit of the PBAF chromatin-remodeling complex. BAF180 is a regulator of 
p53-dependent transcriptional activity and promotes genome stability through cohesion of chromatin at centromeres. SETD2, a histone H3 lysine 36 trimethylating enzyme, 
contributes to the maintenance of genome integrity through suppression of replication stress and promotion of homologous recombination (HR) repair. BAP1, an H2A deubiq-
uitinase, participates in HR repair and prevents chromosomal instability through modulation of various substrates, including MCRS1 and INO80. BAP1 mutations are mutually 
exclusive with PBRM1 mutations and independently predict poor clinical outcome. PBRM1, SETD2, and BAP1 reside within the region of chromosome 3p that is frequently lost 
in RCC; thus, their mutation results in bi-allelic inactivation. PI3K pathway is activated through mutations in PIK3CA, MTOR, TSC1/2, and PTEN, providing a rationale for the 
observed therapeutic efficacy of mTOR inhibitors. CcRCC is characterized by both focal and arm-level recurrent copy-number variants involving, among others, 3p, 5q, 7q, 8p, 
9p, and 14q.
Papillary
Consistent with their common origin in the proximal tubule, papillary RCC and ccRCC have partially overlapping mutational profiles, although VHL inactivation is not a 
feature of papillary RCC. Alterations in MET are associated with type I papillary RCC, while type II is chracterized by alterations of the NFR2-antioxidant response element 
pathway. Loss of CDKN2A, FH mutations, and CpG island methylator phenotype are associated with poor prognosis. Gain of chromsomes 7 (where MET is located) and 17 are 
the most common copy-number events. The most frequent loss is 3p, which when combined with mutations in SETD2 or BAP1 results in biallelic inactivation of these tumor 
supressor genes.
Chromophobe
Only two genes were significantly mutated in the studies of chromophobe RCC: TP53 (32%) and PTEN (9%). Recurrent copy-number variants involve most or all of chromo-
somes 1, 2, 6, 10, 13, and 17, while recurrent structural rearrangements involve the TERT promoter region.
Tumor Evolution and Intratumor Heterogeneity
Multiregional genomic profiling of ccRCCs has revealed profound intratumor heterogeneity with two-thirds of somatic mutations not shared by every region sampled. 
Critically, the majority of known driver events are frequently subclonal, with VHL mutations and loss of 3p being the only consistently clonal (shared) events. These observa-
tions indicate the need for optimizing tumor sampling when evaluating the genomic landscape of ccRCC. Findings of parallel evolution involving the epigenetic modifiers and 
mutational convergence on the components of the PI3K/AKT signaling indicate strong selective pressure for somatic events affecting particular genes and pathways.
Therapeutics
Seven agents are currently approved for the treatment of metastatic RCC targeting either VEGF (sunitinib, sorafenib, bevacizumab with IFN-α, pazopanib, axitinib) or 
mTOR (temsirolimus and everolimus) pathways, with no validated biomarkers of response. Targeted therapies are ineffective in the treatment of medullary and collecting duct 
carcinomas, which are managed with conventional cytotoxics. Currently approved immunotherapies include interleukin-2 and interferon-α. Recently, the anti-PD1 MoAB, 
nivolumab,  and the combined VEGFR2 and Met inhibitor, cabozantinib, have both shown efficacy against everolimus in the phase 3 trials of patients pre-treated with VEGF 
inhibitors.
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